118.70M
Market cap
Current P/E
4.06x
Forward P/E

About

Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.

Similar securities

Based on sector and market capitalization

Report issue